OpenAI acquires Orchestra Bio to bring AI agents into drug-development operations
OpenAI moves from helping scientists think to helping pharma run programs.
AI NEWS
Past AI News
Chinese and English are the same day. This page lists every item, each with the original link, the author, and the engagement.
This day
October 23, 2026
10 items for 2026-10-23, ranked by combined engagement.
Top 3
Sophont launches Holon-S1 to predict genes and biomarkers from routine pathology slides
Gets molecular-level insight out of slides hospitals already have.
Takes frontier AI out of the browser and into the wet lab, while reshoring drug-discovery chemistry.
All
OpenAI acquires Orchestra Bio to bring AI agents into drug-development operations
OpenAI moves from helping scientists think to helping pharma run programs.
CollapseOpenAI acquires Orchestra Bio to bring AI agents into drug-development operations
OpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate the complex process of drug development. Orchestra’s team and technology will join Rosalind, OpenAI’s life-sciences models and tools, including GPT-Rosalind and Rosalind Workbench. According to OpenAI, scientists and program leads can delegate monitoring and tracking of studies to agents; if a failed manufacturing batch threatens a trial start, the agents map affected activities and compare responses, while people make the call. Deal terms were not disclosed.
Sophont launches Holon-S1 to predict genes and biomarkers from routine pathology slides
Gets molecular-level insight out of slides hospitals already have.
CollapseSophont launches Holon-S1 to predict genes and biomarkers from routine pathology slides
Patients with the same cancer diagnosis often have very different tumor biology, and molecular testing is slow and costly. Sophont’s Holon-S1 predicts spatial gene and pathway activity from routine H&E pathology slides. The company says it beat two other models at predicting spatial gene activity in a controlled comparison and surfaced potentially novel biomarkers in breast and colon cancer. It was evaluated across 16 organ types, more than 15 scanners, and both FFPE and fresh-frozen tissue. It is positioned as a research tool, not a diagnostic.
Ex-OpenAI science lead Kevin Weil launches Warp Sciences with a $215M Series A for AI-and-robotics chemistry labs
Takes frontier AI out of the browser and into the wet lab, while reshoring drug-discovery chemistry.
CollapseEx-OpenAI science lead Kevin Weil launches Warp Sciences with a $215M Series A for AI-and-robotics chemistry labs
Kevin Weil introduced Warp Sciences, applying AI and robotics to develop new medicines faster, with a $215M Series A led by Lightspeed. Co-founders include DJ Patil, FAIR co-founder Mano Paluri and drug hunter Sol Reisberg. Warp is building a next-generation preclinical CRO in the US that makes and tests molecules for drug developers, with no pipeline of its own. Its first service is lead-optimization chemistry, done by chemists at first and progressively automated. Reports put the post-money valuation at $865M.
Ant Ling open-sources Ling-3.0-flash-Sante, a healthcare-enhanced 124B MoE with 5.1B active parameters
A major Chinese lab open-sources a medical model that hospitals and builders can self-host.
CollapseAnt Ling open-sources Ling-3.0-flash-Sante, a healthcare-enhanced 124B MoE with 5.1B active parameters
Ant Group’s Ling team has open-sourced Ling-3.0-flash-Sante, a healthcare-enhanced MoE model with 124B total parameters and 5.1B active per token. Ant says it leads similarly sized models on professional healthcare tasks and complex medical reasoning, reporting 45.73 on HealthBench Professional. It targets real-world healthcare research and workflows, with strengthened deep research, multi-agent collaboration and tool use. Weights are available on Hugging Face.
Microsoft’s MAI-DxO in Science: about 1.7x physician accuracy on emergency cases
A peer-reviewed, head-to-head test of AI diagnosis against working physicians.
CollapseMicrosoft’s MAI-DxO in Science: about 1.7x physician accuracy on emergency cases
Microsoft AI chief Mustafa Suleyman announced that MAI-DxO, Microsoft’s diagnostic system, is published in Science. It simulates a panel of virtual physicians that ask questions, order tests and revise the differential step by step. On MIMIC-IV-ED emergency admissions it reached about 80% accuracy versus about 47% for participating generalists who could use the web, and 83% versus 36% on complex NEJM cases, while ordering fewer tests at lower cost. The paper notes the benchmark is text-only and controlled, with no imaging and no assessment of treatment or patient outcomes.
Radical Numerics launches Omnii-1; AI-designed phages reach a human patient for the first time
AI-designed living therapeutics reach the bedside for the first time.
CollapseRadical Numerics launches Omnii-1; AI-designed phages reach a human patient for the first time
Radical Numerics launched Omnii-1, its most powerful genome language model yet. The company says T7 phage variants designed by Omnii-1 were part of a therapeutic cocktail given to a patient with an antibiotic-resistant E. coli infection under an FDA-authorized single-patient compassionate-use pathway. In lab testing, the cocktail eliminated the patient’s resistant isolate. The company did not disclose clinical outcomes for privacy reasons and stresses that one patient cannot establish safety or efficacy.
Insilico Medicine and Servier hit the first milestone in their AI oncology collaboration
An AI drug-discovery deal moving from signing to paid milestones.
CollapseInsilico Medicine and Servier hit the first milestone in their AI oncology collaboration
Insilico Medicine says its AI-driven oncology collaboration with Servier has reached its first R&D milestone, triggering an undisclosed payment. About 10 months in, the partners have launched two oncology programs on hard-to-drug targets, and both have completed target nomination. The deal is worth up to $888M, including $32M in upfront and near-term R&D payments. Insilico leads AI discovery and early development; Servier handles clinical validation and commercialization.
Abridge signs a system-wide deal with the University of Texas System covering eight health institutions
Ambient clinical AI scales from single hospitals to an entire academic health system.
CollapseAbridge signs a system-wide deal with the University of Texas System covering eight health institutions
Clinical documentation AI company Abridge announced an enterprise-wide agreement with the University of Texas System. Eight UT health institutions gain system-wide access to Abridge, with decision-making kept local. UT’s Dr. Peter McCaffrey discussed what it means for clinicians and patients in Fierce Healthcare.
Coherence Neuro raises $45M from the OpenAI Startup Fund and Founders Fund for AI brain implants against brain tumors
OpenAI money backs brain-computer interfaces aimed at cancer care.
CollapseCoherence Neuro raises $45M from the OpenAI Startup Fund and Founders Fund for AI brain implants against brain tumors
Coherence Neuro, which develops AI models and brain implants to fight brain tumors, raised $45M from the OpenAI Startup Fund and Founders Fund, as first reported by Wired. Its SOMA implant is investigational and not FDA-approved.
Abu Dhabi’s health department signs deals with Isomorphic Labs, WHOOP, AstraZeneca and others on AI drug discovery and prevention
A government folds AI drug discovery and wearable data into its health strategy.
CollapseAbu Dhabi’s health department signs deals with Isomorphic Labs, WHOOP, AstraZeneca and others on AI drug discovery and prevention
At the Abu Dhabi Future Health Summit 2026, the emirate’s Department of Health signed agreements with Isomorphic Labs, WHOOP, Cleveland Clinic Abu Dhabi and AstraZeneca. Per official materials, Isomorphic will build a 24-month AI-enabled preclinical drug-discovery roadmap inside Abu Dhabi’s Trusted Research Environment. WHOOP will run a 24-month cardiometabolic prevention program, and the Cleveland Clinic and AstraZeneca deal focuses on cardiovascular, renal and metabolic clinical trials.